2023
Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus
Kincer L, Joseph S, Gilleece M, Hauser B, Sizemore S, Zhou S, Di Germanio C, Zetterberg H, Fuchs D, Deeks S, Spudich S, Gisslen M, Price R, Swanstrom R. Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus. Nature Microbiology 2023, 8: 260-271. PMID: 36717718, PMCID: PMC10201410, DOI: 10.1038/s41564-022-01306-6.Peer-Reviewed Original ResearchConceptsCentral nervous systemT cell-tropic virusesInfected T cellsCerebrospinal fluidAntiretroviral therapyHIV-1Rebound virusViral loadT cellsMacrophage-tropic HIV-1CSF viral loadSuppressive antiretroviral therapyHIV-1 reservoirMacrophage-tropic virusesHigh viral loadWhite blood cellsTherapy interruptionLatent reservoirLymphoid systemNervous systemSystemic infectionVirus replicationBlood cellsTransient influxVirus
2014
Evolving Character of Chronic Central Nervous System HIV Infection
Price RW, Spudich SS, Peterson J, Joseph S, Fuchs D, Zetterberg H, Gisslén M, Swanstrom R. Evolving Character of Chronic Central Nervous System HIV Infection. Seminars In Neurology 2014, 34: 007-013. PMID: 24715483, PMCID: PMC4120280, DOI: 10.1055/s-0034-1372337.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyCentral nervous systemHuman immunodeficiency virus type 1 (HIV-1) infectionCentral nervous system HIV infectionSystemic infectionVirus type 1 infectionCombination antiretroviral therapyType 1 infectionResource-poor settingsUntreated courseCNS infectionsHIV infectionClinical presentationMotor dysfunctionCNS injuryInflammatory responseNervous systemViral pathogenesisInfectionCharacteristic cognitiveDysfunctionBroad prevalenceHADMarked declineSevere consequences
2008
Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection
Price RW, Spudich S. Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection. The Journal Of Infectious Diseases 2008, 197: s294-s306. PMID: 18447615, PMCID: PMC2628635, DOI: 10.1086/533419.Peer-Reviewed Original ResearchConceptsCNS HIV-1 infectionAntiretroviral therapyHIV-1 infectionType 1 infectionCerebrospinal fluidHuman immunodeficiency virus type 1 (HIV-1) infectionSystemic infectionHIV Type 1 InfectionImmunodeficiency syndrome dementia complexVirus type 1 infectionUntreated systemic infectionCombination antiretroviral therapyCNS opportunistic infectionsMinority of patientsEarly treatment interventionLocal inflammatory reactionPrimary viremiaNeurological progressionOpportunistic infectionsDementia complexAsymptomatic infectionSilent infectionBrain injuryInflammatory reactionHIV-1
2005
Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment
Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. BMC Infectious Diseases 2005, 5: 98. PMID: 16266436, PMCID: PMC1299327, DOI: 10.1186/1471-2334-5-98.Peer-Reviewed Original ResearchConceptsAIDS dementia complexCSF HIV viral loadCSF viral loadAntiretroviral therapyHIV viral loadViral loadCD4 countCerebrospinal fluidCSF pleocytosisCSF infectionHIV infectionSystemic infectionHIV RNACSF WBCNeurological performanceCSF white blood cell countResultsIn cross-sectional analysisWhite blood cell countBlood CD4 countCNS HIV infectionCSF HIV RNAHigher CSF WBCLow CD4 countPersistent plasma viremiaHIV RNA levels